Despite new study, Stanford doctor explains why Johnson & Johnson vaccine is still effective

One headline is raising concerns about Johnson and Johnson’s single-shot vaccine, and whether it’s less effective against the Delta variant.

But experts point out that the new NYU medical school study has not been peer-reviewed and was based on blood samples from several dozen people.

RELATE TO: US health officials flag ‘small’ risk of reaction to J&J COVID-19 vaccine

“This kind of laboratory study isn’t really what we’re looking for. We’re looking for more and more factual data on vaccines over time,” said Stanford infectious disease physician Philip Philip. Grant, who is J&J’s principal investigator, explains. vaccine testing.

“The difference about the Delta variant in my mind is that it’s more infectious; it’s not that it evades the vaccine, it’s that it’s more contagious.”

Dr Grant said what matters now is not who gets which vaccine, but who ends up being hospitalized with the coronavirus, “I think the real data that is growing shows that people who get sick are unvaccinated people who are not “received Moderna, Pfizer, or J&J vaccines.”

VIDEO: Is a 3rd COVID scan necessary? Here’s what the Bay Area experts say

While still 70% effective for moderate to severe disease, in trials the J&J vaccine was less effective than the two-dose mRNA vaccine, which raises questions about whether a single shot is needed. other or not.

Kate Larsen: “In terms of boosters, do you expect it to be just a question of when and not if?

Dr. Philip Grant: “Absolutely right, that’s what I expected.”

Kate Larsen: “Do you expect that boosters for J&J will be needed sooner than boosters for Pfizer and Moderna?

Dr. Philip Grant: “Yes, you have to expect that.”

But the CDC has yet to recommend any boosters and it’s important to point out that the J&J single dose vaccine still works.

“The Johnson & Johnson vaccine has helped me fight COVID,” said Sarah Kishler, a San Jose resident who participated in Dr Grant’s J&J trial. She received the vaccine in November at Stanford.

Kishler says she’s protected because last month she volunteered for a separate Kaiser trial to check for antibodies.

“I found out the next day I tested positive for antibodies,” she said. “I think it’s really good news that seven months after I got the vaccine in the trial, I tested positive for antibodies.”

Meanwhile, Dr. Grant points out that J&J is studying two doses against one. “People can rest assured that they are not being looked down upon.”

Having trouble loading the above tracker? Click here to open it in a new window. RELATED STORY & VIDEOS:

Copyright © 2021 KGO-TV. Copyright Registered. | Despite new study, Stanford doctor explains why Johnson & Johnson vaccine is still effective


Inter Reviewed is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – The content will be deleted within 24 hours.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

1 × two =

Back to top button